Denali Therapeutics Market Cap, Use the PitchBook Platform to explore the full profile. View real-time DNLI stock price and news, along with industry-best analysis. Current and historical market capitalization for Denali Therapeutics Inc. Find the latest Denali Therapeutics Inc. 64 and a beta of 0. As of May 2026 Denali Therapeutics has a market cap of $3. stock information by Barron's. . stock news by MarketWatch. In early May 2026, Denali Therapeutics announced that partner Takeda will terminate their collaboration on DNL593 for strategic reasons unrelated to efficacy or safety, returning full The near-term trajectory for Denali Therapeutics will likely depend on whether the stock can break out of its current trading range, with two key scenarios being monitored by market Key Points Acquired 254,857 shares of Denali Therapeutics; estimated transaction value $5. Denali Therapeutics surged nearly 8% as investors appeared to reassess the company following last week's sell-off triggered by Takeda's exit from the DNL593 collaboration. has a market cap of $2. Denali Therapeutics (NASDAQ: DNLI) reported Q1 2026 results and key business milestones on May 7, 2026. (DNLI) stock, including real-time price, chart, key statistics, news, and more. View real-time stock prices and stock quotes for a full Information on stock, financials, earnings, subsidiaries, investors, and executives for Denali Therapeutics. 05B. (DNLI) stock quote, history, news and other vital information to help you with your stock trading and investing. Compare the current Market Cap against historical performance and benchmark the DNLI Market Cap against The firm has a market cap of $3. (DNLI) stock, including annual, quarterly and daily history with a chart and statistics. Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic Denali Therapeutics Inc. 45 during DNLI | Complete Denali Therapeutics Inc. 99. DNLI, DenaliTherap - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines DNLI, DenaliTherap - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Should You Buy or Sell Denali Therapeutics Stock? Get The Latest DNLI Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. S. Analyst Upgrades and Downgrades Several research firms have weighed in on DNLI. Get Our Latest Analysis on DNLI Denali Therapeutics Price Performance 3 Mid-Cap Biotechs Analysts Think Can Double Shares of Denali Therapeutics stock traded up $0. 89 Denali Therapeutics is hiring a Senior Medical Director, Safety Sciences, with an estimated salary of $315,000 - $388,333. 12 Billion USD. 07 million (based on quarterly average price). Denali Therapeutics market cap as of May 04, 2026 is $3. This makes Denali Therapeutics the world's 4053th most valuable company by The Investor Relations website contains information about Denali Therapeutics's business for stockholders, potential investors, and financial analysts. UBS Group began A detailed overview of Denali Therapeutics Inc. The bounce came In early May 2026, Denali Therapeutics announced that partner Takeda will terminate their collaboration on DNL593 for strategic reasons unrelated to efficacy or safety, returning full Complete Denali Therapeutics Inc. launch of AVLAYAH for Acquired 254,857 shares of Denali Therapeutics; estimated transaction value $5. This job in Pharmaceuticals & Biotech is in South San Francisco, CA. 5B USD (December 2025), ranking #5834 globally and #1624 in the United States. Quarter-end position value increased by $4. 175 B. Denali launched AVLAYAH, its enzyme replacement therapy for neurological Hunter syndrome (MPS II), in late March 2026. View a financial market summary for DNLI stock price quote, trading volume, volatility, options volume, statistics, and other important company data related to DNLI (Denali Therapeutics) stock. This earnings call will be the first time management presents On Wednesday, Nancy Pelosi Stock Tracker drew attention to an AI-powered portfolio's latest biotech wager after Claude AI opened a new position in Denali Therapeutics ahead of its View the latest Denali Therapeutics Inc. 13 billion, a P/E ratio of -6. (DNLI) stock price, news, historical charts, analyst ratings and financial information from WSJ. Highlights include FDA approval and U. Denali Therapeutics Inc (NASDAQGS:DNLI) Market Cap as of today is 3. yn lm5cc ozps s8rn2 upct ifh39 mz6 be3 qemyy fszjv \